Inhibitors of C1r/s obtained as recombinant proteins or from human plasma, as used in our in vivo studies, are available in the clinic with a primary indication for the treatment of hereditary angioedema (Feussner et al, 2014). Here, C1R is linked to hereditary angioedema.